Skip to main content
Premium Trial:

Request an Annual Quote

Genedata, CyBio, Biolog, Cellexus Biosystems

Premium
Genedata this week announced the release of its Screener Version 5.0, a data analysis and management solution for screen-to-lead research.
 
The company said that Screener 5.0 combines enterprise assay data management with processing workflows and flexible analysis tools. In addition, it provides access to information from other research and drug discovery systems.
 

 
CyBio this week introduced the CyBi-GeneRobots, a product family of functionally designed systems to automate applications in molecular biology.
 
The CyBi-DiluSpro is an eight channel pipettor that the company said is appropriate for many molecular biology applications. With the help of the CyBio Composer software, application-specific protocols can be programmed and run.
 
The CyBi-Well vario is a multi-channel pipettor that is appropriate for nucleic acid transfer applications in the 96-, 384-, and 1536-well format, such as high-throughput siRNA screening. 
 
The CyBi-RoboSpense is an all-purpose pipetting robot with four or eight individually addressable channels that the manufacturer said is appropriate for nucleic acid purification, processing, and analysis applications. The system works with tubes and plates both in the 96- and 384-well format. The CyBi-RoboSpense is designed for fully automated sample purification and reaction set- and clean-up tasks.
 

 
Biolog this week announced the expansion of its Phenotype MicroArray product line to enable nearly 1,500 simultaneous phenotypic assays of human and other mammalian cells.
 
The first PM assays for mammalian cells, released in December 2005, measure the in vivo activity of about 400 potential energy-producing pathways of cells.
 
Now Biolog has added capabilities to measure many additional phenotypes as well as a greater diversity of phenotypes: nitrogen metabolism assays (approximately 300); ion, ;hormone, and metabolic effector assays (approximately 400); and cytotoxic anti-cancer drug assays (approximately 400).
 

 
Cellexus Biosystems this week launched its new flagship single-use bioreactor CellMaker PLUS for the culture of all cell types. 
 
The CellMaker PLUS combines the principles of airlift with those applied in stirred tank reactors in a single-use culture bag, the HybridBag.
 
The company said that the HybridBag has a “novel shape” that improves mixing and dissolved gas control. Mixing and aeration in the HybridBag occurs from top-to-bottom. This is achieved by using the flow of aeration gases from the integrated sparge tube and the use of integrated propellers, all of which are disposable.
 
In addition, new oxygen sensors called Widgets are now integrated as standard in all HybridBags. Widgets are used to measure the concentration of dissolved oxygen and data is fed back to the new CellMaker PLUS Controller, which then regulates and adjusts the flow of air, nitrogen, and carbon dioxide to the cells. A similar Widget sensor is integrated into the HybridBag to measure pH.
 
The CellMaker PLUS will launch at the BioProcess International conference in Boston Oct. 1-4.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.